Biopharmaceutic Classification System: A Scientific Framework for Pharmacokinetic Optimization in Drug Research
The DOI matches its Crossref record.
Abstract
The tenets of biopharmaceutics, solubility and permeability, are of pivotal importance in new drug discovery and lead optimization due to the dependence of drug absorption and pharmacokinetics on these two properties. A classification system for drugs based on these two fundamental parameters, Biopharmaceutic Classification System (BCS), provides drug designer an opportunity to manipulate structure or physicochemical properties of lead candidates so as to achieve better "deliverability". Considering the facts for failure of NCEs, drug research, once concentrating on optimizing the efficacy and safety of the leads, dramatically transformed in the past two decades. With the enormous number of molecules being synthesized using combinatorial and parallel synthesis, high throughput methodologies for screening solubility and permeability has gained significant interest in pharmaceutical industry. Ultimate aim of the drug discovery scientist in pharmacokinetic optimization is to tailor the molecules so that they show the features of BCS class I without compromising on pharmacodynamics. Considerations to optimize drug delivery and pharmacokinetics right from the initial stages of drug design propelled need for "High Throughput Pharmaceutics" (HTP). In silico predictions and development of theoretical profiles for solubility and lipophilicity provides structure based biopharmaceutical optimization, while in vitro experimental models (microtitre plate assays and cell cultures) validate the predictions. Thus, biopharmaceutical characterization during drug design and early development helps in early withdrawal of molecules with insurmountable developmental problems associated with pharmacokinetic optimization.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although immunotherapy is often applied parenterally, the oral administration route is preferred due to higher compliance of patients and lower complication rates [1].”
From Use of lectin-functionalized particles for oral immunotherapy (2012) · cites this paper as [1]
In the citing paper
“Its main advantage over subcutaneous injections is the painless application resulting in a higher patient compliance [1].”
From Characterization of Vibrio cholerae neuraminidase as an immunomodulator for novel formulation of oral allergy immunotherapy (2018) · cites this paper as [1]
Citations
Cites
Still being checked.
Cited by
High throughput solubility measurement in drug discovery and development
Alsenz, J., & Kansy, M. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.007 · Cited by 412
Varma, M. V. S., & Panchagnula, R. (2005) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.04.003 · Cited by 361
Self-citationPredicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)
Varma, M. V., Steyn, S. J., Allerton, C., & El-Kattan, A. F. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1749-4 · Cited by 334
Self-citationVarma, M. V. S., Obach, R. S., Rotter, C., Miller, H. R., Chang, G., Steyn, S. J., El-Kattan, A., & Troutman, M. D. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901371v · Cited by 331
Self-citationPreparation and investigation of novel gastro-floating tablets with 3D extrusion-based printing
Li, Q., Guan, X., Cui, M., Zhu, Z., Chen, K., Wen, H., Jia, D., Hou, J., Xu, W., Yang, X., et al. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.10.037 · Cited by 222
Solubility and Dissolution Profile Assessment in Drug Discovery
Sugano, K., Okazaki, A., Sugimoto, S., Tavornvipas, S., Omura, A., & Mano, T. (2007) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.22.225 · Cited by 212
Varma, M. V., Gardner, I., Steyn, S. J., Nkansah, P., Rotter, C. J., Whitney-Pickett, C., Zhang, H., Di, L., Cram, M., Fenner, K. S., et al. (2012) · Molecular Pharmaceutics · doi:10.1021/mp2004912 · Cited by 164
Self-citationBiopharmaceutics classification system
Chavda, H., Patel, C. N., & Anand, I. (2010) · Systematic Reviews in Pharmacy · doi:10.4103/0975-8453.59514 · Cited by 162
Targeting Intestinal Transporters for Optimizing Oral Drug Absorption
Varma, M. V. S., Ambler, C. M., Ullah, M., Rotter, C. J., Sun, H., Litchfield, J., Fenner, K. S., & El‐Kattan, A. F. (2010) · Current Drug Metabolism · doi:10.2174/138920010794328850 · Cited by 138
Self-citationIn Silico Prediction of Caco‐2 Cell Permeability by a Classification QSAR Approach
Pham‐The, H., González‐Álvarez, I., Bermejo, M., Sanjuan, V. M., Centelles, I., Garrigues, T., & Cabrera‐Pérez, M. Á. (2011) · Molecular Informatics · doi:10.1002/minf.201000118 · Cited by 134
Lu, T., Yang, J., Gao, X., Chen, P., Du, F., Sun, Y., Wang, F., Xu, F., Shang, H., Huang, Y., et al. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.021592 · Cited by 128
Hastedt, J. E., Bäckman, P., Clark, A. R., DOUB, W. H. J., Hickey, A. J., Hochhaus, G., Kuehl, P. J., Lehr, C., Mauser, P. J., McConville, J. T., et al. (2016) · AAPS Open · doi:10.1186/s41120-015-0002-x · Cited by 125
Oral Absorption, Intestinal Metabolism and Human Oral Bioavailability
El-Kattan, A., & Varm, M. (2012) · Topics on Drug Metabolism · doi:10.5772/31087 · Cited by 102
Enhanced Intestinal Absorption of Daidzein by Borneol/Menthol Eutectic Mixture and Microemulsion
Shen, Q., Li, X., Li, W., & Zhao, X. (2011) · AAPS PharmSciTech · doi:10.1208/s12249-011-9672-4 · Cited by 119
Patil, J. S., & Kadam, D. (2010) · Cited by 109
Su, J., Lai, H., Chen, J., Li, L., Wong, Y., Chen, T., & Li, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063502 · Cited by 107
Di, L., Feng, B., Goosen, T. C., Lai, Y., Steyn, S. J., Varma, M. V. S., & Obach, R. S. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054031 · Cited by 107
Self-citationIssa, M. G., & Ferraz, H. G. (2011) · Dissolution Technologies · doi:10.14227/dt180311p6 · Cited by 106
Idris, M. O., Yekeen, A. A., Alakanse, O. S., & Durojaye, O. A. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1792346 · Cited by 103
Biopharmaceutics Classification System: A Regulatory Approach
Reddy, B. B. K., & Karunakar, A. (2011) · Dissolution Technologies · doi:10.14227/dt180111p31 · Cited by 101
Paxton, J. W. (2012) · InTech eBooks · doi:10.5772/1180 · Cited by 96
Jain, A. K., Swarnakar, N. K., Das, M., Godugu, C., Singh, R. P., Rao, P. R., & Jain, S. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200011f · Cited by 89
Self-citationFunctional role of P-glycoprotein in limiting peroral drug absorption: optimizing drug delivery
Varma, M. V. S., Perumal, O., & Panchagnula, R. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.06.015 · Cited by 89
Self-citationLarregieu, C. A., & Benet, L. Z. (2014) · Molecular Pharmaceutics · doi:10.1021/mp4007858 · Cited by 88
Disease, destination, dose and delivery aspects of ciclosporin: the state of the art
Italia, J. L., Bhardwaj, V., & Kumar, M. N. V. R. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.07.015 · Cited by 85
MCM-41 for furosemide dissolution improvement
Ambrogi, V., Perioli, L., Pagano, C., Latterini, L., Marmottini, F., Ricci, M., & Rossi, C. R. (2011) · Microporous and Mesoporous Materials · doi:10.1016/j.micromeso.2011.07.007 · Cited by 85
Golla, K., Bhaskar, C., Ahmed, F., & Kondapi, A. K. (2013) · Journal of Cancer · doi:10.7150/jca.7093 · Cited by 85
Varma, M. V. S., & Panchagnula, R. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20309 · Cited by 81
Self-citationZhang, Y., Wang, R., Wu, J., & Shen, Q. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.02.013 · Cited by 76
Sharma, P. K., Varma, M. V. S., Chawla, H. P. S., & Panchagnula, R. (2005) · Il Farmaco · doi:10.1016/j.farmac.2005.08.008 · Cited by 74
Self-citationRai, M., Paudel, N., Sakhrie, M., Gemmati, D., Khan, I. A., Tisato, V., Kanase, A., Schulz, A., & Singh, A. V. (2023) · Livers · doi:10.3390/livers3030032 · Cited by 69
Dissolution Enhancement of Drugs. Part II: Effect of Carriers
Saharan, V. A., Kukka, V., Kataria, M. K., Gera, M., & Choudhury, P. K. (2009) · International Journal of Health Research · doi:10.4314/ijhr.v2i3.47904 · Cited by 67
Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation
Hong, J. W., Lee, I., Kwak, Y. H., Park, Y., Sung, H. C., Kwon, I. C., & Chung, H. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0261 · Cited by 63
Fagerberg, J. H., & Bergström, C. A. S. (2015) · Therapeutic Delivery · doi:10.4155/tde.15.45 · Cited by 57
Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer
Bakrania, A. K., Variya, B. C., & Patel, S. S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.023 · Cited by 57
Xiang, H., McSurdy-Freed, J. E., Moorthy, G. S., Hugger, E. D., Bambal, R. B., Han, C., Ferrer, S. B., Gargallo, D. V., & Davis, C. B. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20681 · Cited by 54
Fromin vivotoin vitro/in silicoADME: progress and challenges
Waterbeemd, H. V. D. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.1.1 · Cited by 47
El‐Kattan, A. F., Varma, M. V. S., Steyn, S. J., Scott, D. O., Maurer, T. S., & Bergman, A. J. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-2024-z · Cited by 46
Self-citationPEG-derivatized octacosanol as micellar carrier for paclitaxel delivery
Chu, B., Qu, Y., Huang, Y., Zhang, L., Chen, X., Long, C., He, Y., Ou, C., & Qian, Z. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.01.030 · Cited by 46
Ye, Q., Woo, M. W., & Selomulya, C. (2018) · Food Chemistry · doi:10.1016/j.foodchem.2018.12.074 · Cited by 45
Anti-Cancer Activity of Bromelain Nanoparticles by Oral Administration
Bhatnagar, P., Patnaik, S., Srivastava, A. K., Mudiam, M. K. R., Shukla, Y., Panda, A. K., Pant, A. B., Kumar, P., & Gupta, K. C. (2014) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2014.1997 · Cited by 45
Wu, J., Yang, Y., Yuan, X., Xu, H., Chen, Q., Ren, R., Zhang, Q., Hou, Z., Fang, J., & Yin, D. (2020) · Food & Function · doi:10.1039/d0fo02179b · Cited by 43
In Silico Models to Predict Oral Absorption
Waterbeemd, H. V. D. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00145-0 · Cited by 41
Use of lectin-functionalized particles for oral immunotherapy
Diesner, S. C., Wang, X.-Y., Jensen-Jarolim, E., Untersmayr, E., & Gabor, F. (2012) · Therapeutic Delivery · doi:10.4155/tde.11.146 · Cited by 40
Bang, C. S., Kruse, R. L., Johansson, K. U. I., & Persson, K. (2016) · BMC Microbiology · doi:10.1186/s12866-016-0678-7 · Cited by 39
Computational models to predict aqueous drug solubility, permeability and intestinal absorption
Bergström, C. A. S. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.4.613 · Cited by 38
Liu, M., Lai, Z., Zhu, L., Ding, X., Tong, X., Wang, Z., Bi, Q., & Tan, N. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105931 · Cited by 35
Varma, M. V. S., & Panchagnula, R. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20489 · Cited by 35
Self-citationInorganic matrices: an answer to low drug solubility problem
Perioli, L., & Pagano, C. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.733693 · Cited by 34
The utility of rat jejunal permeability for biopharmaceutics classification system
Zakeri‐Milani, P., Valizadeh, H., Tajerzadeh, H., & Islambulchilar, Z. (2009) · Drug Development and Industrial Pharmacy · doi:10.3109/03639040903037199 · Cited by 32
Golla, K., Reddy, P. S., Bhaskar, C., & Kondapi, A. K. (2013) · Drug Delivery · doi:10.3109/10717544.2013.801051 · Cited by 32
Yang, Q., Wang, Q., Feng, Y., Wei, Q., Sun, C., Firempong, C. K., Adu‐Frimpong, M., Li, R., Bao, R., Toreniyazov, E., et al. (2019) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2019.1594885 · Cited by 30
Biomagnetic Methods: Technologies Applied to Pharmaceutical Research
Corá, L. A., Américo, M. F., de Oliveira, R. B., Serra, C. H. D. R., Baffa, O., Evangelista, R. C., Oliveira, G. F., & Miranda, J. R. D. A. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0285-5 · Cited by 30
Sharma, P. K., Varma, M. V. S., Chawla, H. P. S., & Panchagnula, R. (2005) · Il Farmaco · doi:10.1016/j.farmac.2005.08.006 · Cited by 29
Self-citationPerioli, L., Mutascio, P., & Pagano, C. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0857-7 · Cited by 28
Lilienberg, E., Barbier, C. E., Nyman, R. S., Hedeland, M., Bondesson, U., Axén, N., & Lennernäs, H. (2013) · Molecular Pharmaceutics · doi:10.1021/mp4002574 · Cited by 25
Therapeutic Deep Eutectic Systems for the Enhancement of Drug Bioavailability
Santos, F., & Duarte, A. R. C. (2020) · Environmental chemistry for a sustainable world · doi:10.1007/978-3-030-53069-3_3 · Cited by 23
Synthesis and biological evaluation of l-valine-amidoximeesters as double prodrugs of amidines
Kotthaus, J., Hungeling, H., Reeh, C., Kotthaus, J., Schade, D., Wein, S., Wolffram, S., & Clement, B. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.01.066 · Cited by 22
Iterative Stochastic Elimination for Solving Complex Combinatorial Problems in Drug Discovery
Stern, N., & Goldblum, A. (2014) · Israel Journal of Chemistry · doi:10.1002/ijch.201400072 · Cited by 22
pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs
Varma, M. V. S., Sarkar, M., Kapoor, N., & Panchagnula, R. (2004) · Journal of Chromatography B · doi:10.1016/j.jchromb.2004.11.040 · Cited by 21
Self-citationMesoporous Silica MCM-41 as a Carriers Material for Nystatine Drug in Delivery System
Albayati, T. M., & Alkafajy, A. M. (2019) · Al-Khwarizmi Engineering Journal · doi:10.22153/kej.2019.11.003 · Cited by 19
Enhancement of the intestinal absorption of bortezomib by self-nanoemulsifying drug delivery system
Mahmoudian, M., Valizadeh, H., Löbenberg, R., & Zakeri‐Milani, P. (2019) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2019.1699109 · Cited by 18
Vascular Pathology as a Potential Therapeutic Target in SCI
Benton, R. L., & Hagg, T. (2011) · Translational Stroke Research · doi:10.1007/s12975-011-0128-7 · Cited by 18
Sistema de classificação biofarmacêutica e bioisenções
Bonamici, D. (2009) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.9.2009.tde-29032010-151226 · Cited by 18
Pharmacokinetics: Theory and Application in Drug Discovery and Development
Sharma, P. K., Patel, N. K., Prasad, B., & Varma, M. V. S. (2021) · Springer eBooks · doi:10.1007/978-981-15-5534-3_11 · Cited by 18
Self-citationXu, Y.-A., Fan, G., Gao, S., & Hong, Z. (2008) · Drug Development and Industrial Pharmacy · doi:10.1080/03639040701484668 · Cited by 17
An Overview of the Field of Peptide and Protein Delivery
van der Walle, C. F., & Olejnik, O. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-384935-9.10001-x · Cited by 14
Essa, E. A., & Dwaikat, M. (2015) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2015.54.s8 · Cited by 14
An in-depth review of PPARγ modulators as anti-diabetes therapeutics
Jangra, A., Babu, B., Selvaraj, D., Byran, G., Rajan, S., Jangra, S., & Malakar, V. K. (2025) · Drug Metabolism Reviews · doi:10.1080/03602532.2025.2508152 · Cited by 14
Zhang, J. Y., Zhang, J.-W., Kiffe, M., Walles, M., Jin, Y., Blanz, J., Dayer, J., Sánchez, A., Zhang, C., Zhang, L., et al. (2021) · Xenobiotica · doi:10.1080/00498254.2021.2005852 · Cited by 13
Alsenz, J. (2012) · Wiley eBooks · doi:10.1002/9780470921920.edm066 · Cited by 13
Helmy, S. A., Elbedaiwy, H. M., & El-Masry, S. M. (2020) · Therapeutic Delivery · doi:10.4155/tde-2020-0042 · Cited by 11
Diesner, S. C., Bergmayr, C., Wang, X.-Y., Heiden, D., Exenberger, S., Roth-Walter, F., Starkl, P., Ret, D., Pali-Schöll, I., Gabor, F., et al. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.03.017 · Cited by 9
Zagade, A. D., Shard, A., Shinde, S., Sahu, A. K., & Sengupta, P. (2020) · Journal of Chromatographic Science · doi:10.1093/chromsci/bmaa044 · Cited by 9
Investigating Intestinal Permeability of Bortezomib Using a Validated HPLC-UV Method
Mahmoudian, M., Zakeri‐Milani, P., & Valizadeh, H. (2018) · Drug Research · doi:10.1055/s-0043-115648 · Cited by 9
In Vitro Bioavailability Study of an Antiviral Compound Enisamium Iodide
Haltner‐Ukomadu, E., Gureyeva, S. N., Oleksii, B., Goy, А. М., Mueller, L., Grygorii, K., & Margitich, V. (2018) · Scientia Pharmaceutica · doi:10.3390/scipharm86010003 · Cited by 8
A Modified Approach to Predict Dissolution and Absorption of Polydisperse Powders
Butcher, J. C., Garg, S., Kim, D., & Sharma, P. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9630-3 · Cited by 8
Self-citationThe Why and How of Absorption, Distribution, Metabolism, Excretion, and Toxicity Research
Waterbeemd, H. V. D., & Testa, B. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00116-4 · Cited by 8
Yoshida, N., Takagi, A., Kitazawa, H., Kawakami, J., & Adachi, I. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20563 · Cited by 8
Optimizing Lead Compounds: The Role of Artificial Intelligence in Drug DiscoveryPreprint
Niazi, S. K., Mariam, Z., & Magoola, M. (2024) · Preprints.org · doi:10.20944/preprints202404.0055.v1 · Cited by 8
Nofsinger, R., & Borchardt, R. T. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23079 · Cited by 7
Alakanse, O. S., Joel, I. Y., Ambrose, G. O., Adigun, T. O., Sulaiman, F. A., Nkechinyere, O. J., Idris, M. O., Abiodun, Y. A., & Durojaye, O. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90769-9.00021-9 · Cited by 6
In vivo rat PK profiling in drug discovery: new challenges
Zonzini, L., Bianchi, F., Cesari, N., & Sartori, M. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2010.509396 · Cited by 6
Plantamura, Y. S., Allo, M. Á., Riedel, J., Fuentes, P., Riesco, A. S., Bernabeu, E., Garcés, M., Evelson, P., Gorzalczany, S. B., Carranza, A., et al. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03537-2 · Cited by 5
He, Y., Hu, Q., & Sun, X. (2022) · Journal of Nanomaterials · doi:10.1155/2022/6541132 · Cited by 5
Enhancement of Carvedilol Dissolution; Surface Solid Dispersion Versus Solid Dispersion
Essa, E. A. (2015) · Asian Journal of Pharmaceutics · doi:10.22377/ajp.v9i4.469 · Cited by 5
Hadžiabdić, J., Elezović, A., Hadžović, S., & Vehabović, M. (2013) · International Journal of Science Technology and Society · doi:10.11648/j.ijsts.20130101.14 · Cited by 5
Dissolution and Duodenal Permeation Characteristics of Lovastatin from Bile Salt Solid Dispersions
Chun, I. (2009) · Journal of Korean Pharmaceutical Sciences · doi:10.4333/kps.2009.39.2.097 · Cited by 5
INVESTIGATING PHARMACEUTICAL CO-CRYSTALS AS A MEANS TO IMPROVE THE SOLUBILITY OF A DRUG
Brown, R. A. (2012) · KU ScholarWorks (The University of Kansas) · Cited by 3
Imtiaz, M., Biswas, P., Tareq, M. M. I., Shovon, M. H. J., Tauhida, S. J., Zilani, M. N. H., & Hasan, M. N. (2025) · In Silico Pharmacology · doi:10.1007/s40203-025-00436-z · Cited by 2
Alsafar, Z. F., & Sabar, A.-L. M. (2023) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2023.00410 · Cited by 2
The Why and How of Absorption, Distribution, Metabolism, Excretion, and Toxicity Research
Waterbeemd, H. V. D., & Testa, B. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.02586-5 · Cited by 2
Mansour, S. R., El-Hak, H. N. G., & Moustafa, A. A. (2018) · Gastroenterology & Hepatology Open Access · doi:10.15406/ghoa.2018.09.00337 · Cited by 2
Avaliação do impacto de diferentes variáveis no ensaio de dissolução intrínseca de metronidazol
Issa, M. G. (2011) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.9.2011.tde-15072011-104145 · Cited by 2
FORMULATION AND EVALUATION OF LIQUISOLID COMPACTS OF ACECLOFENAC
Molli, B. S., Rao, G. K., Nagamani, B., & Devi, P. U. (2017) · International Journal of Advances in Pharmacy and Biotechnology · doi:10.38111/ijapb.20170303001 · Cited by 1
Chaudhari, S. M., & Thagale, R. (2026) · Oriental Journal Of Chemistry · doi:10.13005/ojc/420313 · Cited by 1
Moinuddin, S. K., Srikanth, P., Sharma, P., & Nandi, S. (2023) · Journal of Chromatographic Science · doi:10.1093/chromsci/bmad090 · Cited by 1
Self-citationMetabolismus und Bioverfügbarkeit von Serinprotease Inhibitoren und ihren Amidoxim-Prodrugs
Kotthaus, J. (2008) · Multimedialen Archiv und Publikationsserver der Christian-Albrechts-Universität zu Kiel (Christian-Albrechts-Universität zu Kiel) · Cited by 1
Desenvolvimento de Nanopartículas Lipídicas com Paclitaxel para Tratamento do Glioma
Ferreira, M. S. P. (2015) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/69wd-yd48 · Cited by 1
Neue Prodrug-Prinzipien für Amidine
Reeh, C. (2008) · Multimedialen Archiv und Publikationsserver der Christian-Albrechts-Universität zu Kiel (Christian-Albrechts-Universität zu Kiel) · Cited by 1
Metadata
- Authors
- Varma, M., Khandavilli, S., Ashokraj, Y., Jain, A., Dhanikula, A., Sood, A., Thomas, N., Pillai, O., Sharma, P., Gandhi, R., Agrawal, S., Nair, V., & Panchagnula, R.
- Affiliations
- National Institute of Pharmaceutical Education and Research (IN)
- Corresponding author
- Panchagnula, Ramesh
- Venue
- Current Drug Metabolism
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2004-10-01
- Volume
- 5
- Issue
- 5
- Pages
- 375-388
- ISSN
- 1389-2002 (ISSN-L)
- OpenAlex
- W2001958300
- Cited by
- 107
- References
- 0
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 2 · 2021: 3 · 2020: 5 · 2019: 4 · 2018: 5 · 2017: 3 · 2016: 6 · 2015: 4 · 2014: 4 · 2013: 6 · 2012: 9
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Drug Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- solubility, permeability, drug absorption, pharmacokinetic optimization, lead optimization, new chemical entities, high-throughput screening, lipophilicity prediction, structure-based drug design, in vitro permeability model
- MeSH terms
- Animals, Biopharmaceutics, Chemistry, Pharmaceutical, Pharmaceutical Preparations, Humans, Intestinal Absorption, Pharmacokinetics, Pharmacology, Clinical, Research, Solubility
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.